Precision for Medicine and PathAI Announce Strategic Collaboration to Advance AI-Powered Clinical Trial Services and Biospecimen Products
Collaboration will deliver innovative AI-powered pathology tools and quality control enhancements to accelerate clinical trials and biomarker discovery
BOSTON and FREDERICK, Md., April 25, 2025 /PRNewswire/ -- Precision for Medicine, a leading provider of next generation drug development research and services, and PathAI, a global leader in digital pathology, today announced a strategic collaboration to partner on developing novel AI-based technologies and to integrate PathAI's advanced digital pathology and analysis capabilities across Precision for Medicine's clinical trial and biospecimen operations.
This collaboration includes use of several PathAI technologies and establishes an agreement to offer novel tools and analytical services that address emerging needs in biomarker discovery, spatial biology, and tissue-based clinical research. Through this collaboration PathAI's tools and services will help augment Precision for Medicine's proprietary pipeline providing biopharma clients with access to imaging workflows offered through Precision for Medicine's integrated laboratory and clinical trial services.
'Together, we're deploying tools that add critical quality control steps to tumor biopsy workflows and apply machine-based learning and unsupervised algorithms early in the development cycle to help identify which biomarkers are most relevant for clinical efficacy,' said Darren Davis, PhD, Senior Vice President Global Digital Pathology, Genomics and Liquid Biopsy Solutions. 'Precision for Medicine's CLIA compliant laboratory enables precise patient stratification and accelerate decision-making in clinical trials, ultimately supporting success in areas of high unmet need.'
As part of the agreement, Precision for Medicine will deploy select tools from PathAI, including AISight®, a digital pathology image management system, and other AI-powered algorithms to enhance biospecimen and clinical trial services. These tools will enable the application of validated, algorithm-based quality control steps to biospecimen analysis, improving consistency and data reliability.
The collaboration will also support the use of PathAI's leading AI capabilities leveraging best in class machine learning based models to enhance Precision for Medicine multi-modal datasets. The technology reduces large, complex biomarker panels to scalable, and actionable, biomarkers to help interpret complex tissue biology to complement translational research programs. Additionally, the companies will work together to analyze complex tissue biology empowering biopharma clients to understand and identify the right patients for the right therapies, faster.
'At PathAI, our mission is to harness the power of artificial intelligence to improve the accuracy, depth, and efficiency of pathology-driven insights,' said Andy Beck, MD, PhD, Co-founder and CEO of PathAI. 'We are thrilled to collaborate with Precision for Medicine to help advance our mission and deliver differentiated value to our mutual customers.'
Precision's collaboration with PathAI brings unique value to biopharma clients by combining these AI tools with proprietary wet lab infrastructure, centralized clinical trial operations, and scientific oversight. The innovative tools generated through this collaboration will only be available through Precision for Medicine's services, providing a level of integration and customization not offered elsewhere in the industry.
'This collaboration enhances how we're using our biospecimen business by enabling deeper, more informative analyses of the tissue samples we provide to our clients,' said Cullen Taylor, MD, Medical Director at Precision for Medicine. 'We're adding an entirely new layer of cellular-level insight on top of already well-annotated sequenced samples, going far beyond what traditional pathology assessments can offer. It's a meaningful step forward in how we support biomarker discovery, enhancing datasets for diagnostic validation and therapeutic development.'
About Precision for Medicine
Precision for Medicine is the first biomarker-driven clinical research and development services organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies a transformational approach to clinical research that integrates clinical trial design and execution with deep scientific knowledge, laboratory expertise, data sciences and advanced manufacturing solutions. This convergence is driving faster clinical development and approval. Precision for Medicine is part of Precision Medicine Group, with 3,500 people in 40 locations globally across North America, Europe and Asia-Pacific. For more information, visit precisionformedicine.com
Contact
Andie Lunkenheimer
[email protected]
About PathAI
PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming diagnostic accuracy and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, please visit pathai.com
Contact
Owen Blaschak
[email protected]
Footnote
1AISight is for Research Use Only in the US; AISight Dx is CE-IVDR in Europe and UKCA in UK
View original content to download multimedia: https://www.prnewswire.com/news-releases/precision-for-medicine-and-pathai-announce-strategic-collaboration-to-advance-ai-powered-clinical-trial-services-and-biospecimen-products-302438551.html
SOURCE PRECISION FOR MEDICINE
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Bio Usawa Biotechnology and Bioeq AG Partner to Create Widespread Access to Vision-Saving Medicine Across Sub-Saharan Africa
Landmark partnership will democratize access to critical eye treatment for millions facing preventable blindness from diabetes complications KIGALI, Rwanda and SAN FRANCISCO and ZUG, Switzerland , July 01, 2025 (GLOBE NEWSWIRE) -- Bio Usawa Biotechnology Ltd. (Bio Usawa) and Bioeq AG today announced a groundbreaking agreement that will bring a life-changing biosimilar medicine—ranibizumab, used to treat serious retinal diseases—within reach for millions across Sub-Saharan Africa. This partnership grants Bio Usawa exclusive rights to register and commercialize Bioeq's ranibizumab biosimilar under the brand name BioUcenta™, marking a critical step forward in democratizing access to essential biologic therapies across the region. Ranibizumab, a biosimilar to Lucentis®, is a monoclonal antibody used to treat diabetic macular edema (DME), wet age-related macular degeneration (AMD), and other blinding retinal diseases. While this breakthrough therapy has been transforming lives in higher-income countries for nearly 20 years, patients across Africa have been denied access due to prohibitive costs and limited availability. This partnership aims to end that disparity, bringing hope to millions who face preventable vision loss. 'By making ranibizumab accessible in Sub-Saharan Africa, we are empowering doctors to save the vision of millions, particularly those suffering complications from diabetes—a disease that is quietly but rapidly becoming one of Africa's greatest health threats,' said Dr. Menghis Bairu, Co-founder, President and CEO of Bio Usawa. "Our partnership with Bio Usawa is core to our commitment to expanding global access to essential medicines," said Martin Huber, Managing Director of Bioeq AG. "Together, we are breaking down the barriers that have denied effective treatment for serious retinal diseases to patients across Sub-Saharan Africa for too long. Bringing a high-quality, affordable ranibizumab biosimilar to this region is a significant step towards health justice." Africa is at the front line of a growing diabetes crisis. According to the International Diabetes Federation, more than 24 million Africans were living with diabetes in 2024, with that number projected to double by 2050. Diabetic retinopathy, a leading complication, threatens the sight of up to one-third of these patients. Without timely intervention, many will face blindness—an outcome that is both preventable and tragic. BioUcenta™, administered via intravitreal injection, works by blocking abnormal blood vessel growth in the retina and preventing fluid leakage—two key causes of vision loss. The biosimilar has already been approved in both Europe and the United States and will now be registered and distributed across Sub-Saharan Africa by Bio Usawa. 'This collaboration is about equity,' added Dr. Bairu. 'Access to advanced biologic therapies should not be a privilege of geography or income. We are proud to work with Bioeq to make this a reality for Africa—ensuring that patients, regardless of where they live, can receive the care they deserve.' The agreement marks the initial fulfillment of Bio Usawa's mission to democratize access to high-quality, affordable, and proven biotherapies in low-middle income countries. By establishing local capabilities and partnerships, the initiative creates a foundation for broader access to essential medicines across the continent. The partnership also represents a new model for global health equity, demonstrating how innovative collaborations can bridge the gap between life-saving medical advances and the patients who need them most. Rather than accepting that cutting-edge treatments remain exclusive to wealthy nations, this agreement shows how strategic partnerships can extend medical breakthroughs to underserved populations. About Bio Usawa Bio Usawa is an African biotechnology company with a mission to expand access to affordable, high-quality biosimilars across the continent. By combining deep industry experience with regional partnerships, Bio Usawa is building a future where life-saving biomedicines are made in Africa, by Africans, for Africans—and beyond. For more information, visit About Bioeq AG Bioeq AG is a Swiss biopharmaceutical joint venture between Polpharma Biologics Group and Formycon AG. Bioeq develops and licenses biosimilars for global markets, combining innovation and quality to improve patient access to vital therapies. Learn more at Media Contact:Daniel LevineLevine Media Group+1 510-280-5405danny@ in to access your portfolio
Business Wire
19 minutes ago
- Business Wire
(Agency for Medicinal Products and Medical Devices of the Republic of Slovenia)
BORDEAUX, France & LJUBLJANA, Slovenia--(BUSINESS WIRE)--FineHeart S.A., a clinical-stage medical technology company specializing in the development of innovative solutions for cardiology, announces that it has received authorization from JAZMP, the Agency for Medicinal Products and Medical Devices of the Republic of Slovenia, to begin its First-In-Human (FIH) clinical study. This prospective, non-randomized study is designed to assess the safety, implant feasibility and preliminary clinical performance of the FlowMaker® device in patients with advanced heart failure. FlowMaker® is a new-generation, fully implantable left ventricular assist device designed to work in synergy with the heart's natural contraction. Less invasive than current devices, this technology aims to preserve native cardiac function while significantly improving patients' quality of life. Professor Ivan Kneževič, cardio surgeon and director of the Transplantation Centre of the University Medical Centre in Ljubljana, will lead the study. " It is a real privilege to take part in this first FIH study. FlowMaker represents a major technological advance in the treatment of patients with advanced heart failure" he said. Arnaud Mascarell, CEO and co-founder of FineHeart, comments: " Following approvals in the Czech Republic and France, the Slovenian authorization represents another strong endorsement of our preliminary clinical results and our technology by European health authorities. It reflects the growing confidence within the cardiology community in our disruptive approach. This latest green light reinforces our clinical strategy across Europe—a critical step toward securing CE marking. Our goal remains clear: to deliver an innovative, less invasive solution for patients with advanced heart failure, where current treatment options remain limited." About FineHeart - FineHeart
Yahoo
3 hours ago
- Yahoo
HyperStrong and Repono forge strategic collaboration to advance grid-scale battery energy storage projects in Europe
ZHUHAI, China, July 1, 2025 /PRNewswire/ -- HyperStrong, a global leading provider of battery energy storage system (BESS) solutions, and Repono AB, a European developer of large-scale energy storage projects, have formalised their strategic collaboration through a Partnering Agreement on 23 June, aimed at jointly advancing 1.4GWh grid-scale energy storage projects across Europe by 2027. The strategic partnership brings together complementary skills required for the rapid, large-scale deployment of electricity storage. Repono's project development expertise including site development, permitting, and grid interconnection, will be complemented by HyperStrong's full-scope system integration capabilities, including BESS solution delivery and associated lifecycle services. The collaboration reflects a shared commitment to accelerating the energy transition, while supporting Europe's ambition to scale local value chains and strengthen long-term industrial resilience. "We are excited to deepen our partnership with Repono to accelerate the deployment of safe, high-performance, and cost-effective energy storage infrastructure in Europe," said Mr. Pingyang Wang, Senior Vice President of HyperStrong International and President of EMEA Region. "This collaboration reflects our long-term commitment to the European market and our shared ambition to enable grid stability and energy transition in the region." Mr. Karim Nils Grueber, CEO of Repono, stated: "HyperStrong brings strong technical know-how and proven experience in delivering integrated BESS solutions which is complementary to Repono's extensive expertise in project development and more than 100,000 hours of BESS operations experience. We will lead with excellence in project design, permitting, and EPC coordination. Together, we aim to unlock the potential of grid-scale storage as a backbone for Europe's energy transition." Mr. Greger Landén, CTO of Repono, also expressed: "We have together with HyperStrong spent the last six months evaluating their technology and approach to the energy storage area. We have not only found a partner that is truly focused on performance and safety that aligns well with our values, but also a great team willing to discuss and develop our common approach in line with our needs for enabling the green transition in the European market." Under the agreement, both parties will engage in joint planning and project reviews, including technical and commercial alignment on identified pipeline projects. The agreement reflects a shared intent to leverage their complementary strengths for mutually beneficial success in future grid-scale projects. ENDS About HyperStrong Beijing HyperStrong Technology Co., Ltd. ("HyperStrong", is a global leading energy storage system (ESS) integrator and service provider. Founded in 2011, with more than 13 years of research and development, as well as experience garnered through more than 300 energy storage projects and more than 30GWh of deployment, HyperStrong offers a portfolio of ESS products and one-stop solutions for the full spectrum of utility-scale, commercial and industrial applications. Having built four smart manufacturing bases, three R&D centers, two testing labs and a global marketing center, HyperStrong empowers clients worldwide to achieve their energy transition and carbon neutrality goals. For more information about HyperStrong, visit: About Repono Repono AB is a Sweden-based energy infrastructure developer focusing on large-scale renewable and storage projects in the European market. Repono's expertise spans project origination, permitting, financing, and coordination of engineering, procurement, and construction (EPC) activities with a focus on leveraging from the operational and software experience within the company. For more information about Repono AB, visit: SOURCE Beijing HyperStrong Technology Co., Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
